Treating metastatic pancreatic ductal adenocarcinoma: NALIRIFOX as new standard?

Pancreatic ductal adenocarcinoma, with an annual number of deaths exceeding 530 000 patients, 1 Kocarnik JM Compton K Dean FE et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022; 8: 420-444 Crossref PubMed Scopus (580) Google Scholar undoubtedly requires new, potent treatment strategies. The Surveillance, Epidemiology, and End Results (SEER) programme demonstrated that in the period from 1977 to 2013, pancreatic ductal adenocarcinoma remained the cancer with the worst 5-year overall survival rate among all common cancers. In this 36-year period, the 5-year overall survival only improved from 2·5% to 8·7%, clearly less than for most other cancers. 2 Our World in DataFive-year cancer survival rates in the USA, all races, total, 1977 to 2013. https://ourworldindata.org/grapher/five-year-cancer-survival-in-usaDate accessed: July 18, 2023 Google Scholar NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trialOur findings support use of the NALIRIFOX regimen as a possible reference regimen for first-line treatment of mPDAC. Full-Text PDF Open Access